Trade OncoCyte Corporation - OCX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0356 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.3722 |
| Open | 3.3622 |
| 1-Year Change | 41.79% |
| Day's Range | 3.2322 - 3.4322 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2025 | 3.4322 | 0.0800 | 2.39% | 3.3522 | 3.4322 | 3.2322 |
| Apr 24, 2025 | 3.3722 | 0.3700 | 12.32% | 3.0022 | 3.3922 | 2.9922 |
| Apr 23, 2025 | 2.9522 | 0.0600 | 2.07% | 2.8922 | 2.9522 | 2.8222 |
| Apr 22, 2025 | 2.9122 | 0.0800 | 2.82% | 2.8322 | 2.9922 | 2.7522 |
| Apr 21, 2025 | 2.8522 | 0.0800 | 2.89% | 2.7722 | 2.8722 | 2.7622 |
| Apr 17, 2025 | 2.7922 | 0.0000 | 0.00% | 2.7922 | 2.8222 | 2.7422 |
| Apr 16, 2025 | 2.8222 | -0.0400 | -1.40% | 2.8622 | 2.9222 | 2.7922 |
| Apr 15, 2025 | 2.9322 | 0.0800 | 2.80% | 2.8522 | 3.0322 | 2.8422 |
| Apr 14, 2025 | 2.7922 | -0.0300 | -1.06% | 2.8222 | 2.8622 | 2.7422 |
| Apr 11, 2025 | 2.7622 | -0.0500 | -1.78% | 2.8122 | 2.8722 | 2.7022 |
| Apr 10, 2025 | 2.8422 | 0.0700 | 2.53% | 2.7722 | 2.9022 | 2.7422 |
| Apr 9, 2025 | 2.8922 | 0.1700 | 6.24% | 2.7222 | 2.9522 | 2.7122 |
| Apr 8, 2025 | 2.7322 | -0.1900 | -6.50% | 2.9222 | 2.9622 | 2.6522 |
| Apr 7, 2025 | 2.7722 | 0.1200 | 4.52% | 2.6522 | 2.8222 | 2.5922 |
| Apr 4, 2025 | 2.6922 | -0.2100 | -7.24% | 2.9022 | 2.9022 | 2.6522 |
| Apr 3, 2025 | 2.9122 | 0.0600 | 2.10% | 2.8522 | 2.9522 | 2.7922 |
| Apr 2, 2025 | 2.9422 | -0.1000 | -3.29% | 3.0422 | 3.0422 | 2.8122 |
| Apr 1, 2025 | 2.9122 | -0.2000 | -6.43% | 3.1122 | 3.1122 | 2.8822 |
| Mar 31, 2025 | 3.0022 | -0.2600 | -7.97% | 3.2622 | 3.3322 | 2.9322 |
| Mar 28, 2025 | 3.2022 | 0.0100 | 0.31% | 3.1922 | 3.2922 | 3.0822 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
OncoCyte Corporation Company profile
About OncoCyte Corp
Oncocyte Corporation is a molecular diagnostics company. The Company is engaged in developing and commercializing laboratory-developed tests (LDTs) to serve unmet medical needs across the cancer care continuum. The LTDs provide actionable information to physicians and patients to optimize treatment decisions, including the selection of immunotherapy. The Company focuses on the development of a non-invasive confirmatory blood test for lung cancer called DetermaDx. The DetermaDx is the test to predict a post-surgery patient’s risk of cancer recurrence and their response to chemotherapy in early-stage lung cancer. Its development pipeline includes TheraSure CNI Monitor, which is a blood-based test for immunotherapy monitoring, and TheraSure Transplant Monitor, a solid organ transplantation monitoring test. Its other DetermaIO, DetermaCNI, DetermaMx, Keytruda, Opdivo, Tecentriq and Imfinzi.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, OncoCyte Corp revenues increased from $1.2M to $7.7M. Net loss increased from $29.9M to $64.1M. Revenues reflect DetermaRx segment increase from $547K to $2.5M, Pharma Services segment increase from $669K to $1.5M, United States segment increase from $742K to $3.5M. Higher net loss reflects Fair Value Adjustments on Other Assets increase from $4M (income) to $27.3M (expense).
| Industry: | Bio Therapeutic Drugs |
15 Cushing
IRVINE
CALIFORNIA 92618
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com